<p>Sangamo Therapeutics（纳斯达克代码：SGMO - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的股票研究人员从 “持有” 评级下调至 “强烈卖出” 评级。</p>
<ul>
<li>2 只低价基因治疗股票值得投机</li>
</ul>
<p>其他一些研究公司也最近对 SGMO 发表了评论。巴克莱在 11 月 7 日的研究报告中重申了 “持平” 评级，并将 Sangamo Therapeutics 的目标股价设定为 1.00 美元（低于 5.00 美元）。HC Wainwright 在 9 月 4 日的研究报告中重申了 “买入” 评级，并将 Sangamo Therapeutics 的目标股价设定为 10.00 美元。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 Sangamo Therapeutics 的 “卖出（e+）” 评级。三位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标股价为 3.83 美元。</p>
<p>获取 <strong>Sangamo Therapeutics</strong> 的提醒：</p>
<p><strong>查看我们关于 SGMO 的最新研究报告</strong></p>
<h2>Sangamo Therapeutics 股票表现</h2>
<p>纳斯达克 SGMO 在周五开盘价为 0.44 美元。该公司的 50 日移动平均价格为 0.59 美元，200 日移动平均价格为 0.56 美元。Sangamo Therapeutics 的 52 周最低价为 0.41 美元，52 周最高价为 2.84 美元。该公司的市值为 1.4964 亿美元，市盈率为-1.53，贝塔值为 1.25。</p>
<p>Sangamo Therapeutics（纳斯达克代码：SGMO - 获取免费报告）在 11 月 6 日发布了其季度财报。这家生物制药公司报告季度每股收益为（0.11 美元），低于共识预期的（0.03 美元）0.08 美元。Sangamo Therapeutics 的股本回报率为-293.05%，净利润率为-77.48%。该公司季度收入为 58 万美元，而分析师预期为 3440 万美元。整体来看，股票分析师预测 Sangamo Therapeutics 在本年度将发布-0.46 美元的每股收益。</p>
<h2>机构投资者对 Sangamo Therapeutics 的看法</h2>
<p>几家大型投资者最近调整了对 SGMO 的持股。Golden State Equity Partners 在第二季度将其在 Sangamo Therapeutics 的持股增加了 5.4%。Golden State Equity Partners 目前拥有 391,943 股该生物制药公司的股票，价值 212,000 美元，在此期间又购买了 20,000 股。World Investment Advisors 在第三季度将其在 Sangamo Therapeutics 的持股增加了 88.5%。World Investment Advisors 目前拥有 42,611 股该生物制药公司的股票，价值 29,000 美元，在上个季度又购买了 20,000 股。Wealth Enhancement Advisory Services LLC 在第二季度将其在 Sangamo Therapeutics 的持股增加了 30.8%。Wealth Enhancement Advisory Services LLC 目前拥有 90,550 股该生物制药公司的股票，价值 48,000 美元，在此期间又购买了 21,300 股。Wealth Management Associates Inc.在第三季度将其在 Sangamo Therapeutics 的持股增加了 9.1%。Wealth Management Associates Inc.目前拥有 335,800 股该生物制药公司的股票，价值 226,000 美元，在上个季度又收购了 28,000 股。最后，Meritage Portfolio Management 在第二季度将其在 Sangamo Therapeutics 的持股增加了 37.3%。Meritage Portfolio Management 目前拥有 127,000 股该生物制药公司的股票，价值 69,000 美元，在此期间又收购了 34,500 股。机构投资者持有该公司 56.92% 的股票。</p>
<h2>Sangamo Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sangamo Therapeutics, Inc.是一家临床阶段的基因治疗公司，专注于将科学转化为药物，以改变美国患者及其家庭的生活，这些患者受到严重疾病的困扰。该公司的临床阶段产品候选者包括 ST-920，一种基因治疗产品候选者，目前正在进行针对 Fabry 病的 1/2 期临床研究；TX200，一种嵌合抗原受体工程调节性 T 细胞（CAR-Treg）治疗产品候选者，目前正在进行针对 HLA-A2 不匹配肾移植中免疫介导排斥的 1/2 期临床研究；SB-525，一种基因治疗产品候选者，目前正在进行针对中度至重度血友病 A 的 3 期临床试验；BIVV003，一种锌指核酸酶基因编辑细胞治疗产品候选者，目前正在进行针对镰状细胞病的 1/2 期 PRECIZN-1 临床研究。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，而不是 Sangamo Therapeutics</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>如果你等到下跌，Micron Technology 可能会让你错过机会</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dNTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dNTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Sangamo Therapeutics 吗？</h2>
<p>在你考虑 Sangamo Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Sangamo Therapeutics 并不在名单上。</p>
<p>虽然 Sangamo Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SGMO

<p>Sangamo Therapeutics（纳斯达克代码：SGMO）被 Wall Street Zen 从 “持有” 评级下调至 “强烈卖出” 评级。巴克莱将目标价设定为 1.00 美元，较之前的 5.00 美元下调，而 HC Wainwright 维持 “买入” 评级，目标价为 10.00 美元。该股票开盘价为 0.44 美元，52 周价格区间为 0.41 美元至 2.84 美元。机构投资者持有该股票的 56.92%。Sangamo 专注于基因医学，拥有多个临床阶段的产品候选者</p>

<p>Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>Sangamo Therapeutics（纳斯达克代码：SGMO - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 的股票研究人员从 “持有” 评级下调至 “强烈卖出” 评级。</p>
</div><ul>
<li>2 low-priced gene therapy stocks to speculate on</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只低价基因治疗股票值得投机</li>
</ul>
</div><p>A number of other research firms have also recently commented on SGMO. Barclays reaffirmed an &#34;equal weight&#34; rating and set a $1.00 price target (down from $5.00) on shares of Sangamo Therapeutics in a research note on Friday, November 7th. HC Wainwright restated a &#34;buy&#34; rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, September 4th. Finally, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Sangamo Therapeutics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $3.83.</p>
<div class="lb-trans"><p>其他一些研究公司也最近对 SGMO 发表了评论。巴克莱在 11 月 7 日的研究报告中重申了 “持平” 评级，并将 Sangamo Therapeutics 的目标股价设定为 1.00 美元（低于 5.00 美元）。HC Wainwright 在 9 月 4 日的研究报告中重申了 “买入” 评级，并将 Sangamo Therapeutics 的目标股价设定为 10.00 美元。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了 Sangamo Therapeutics 的 “卖出（e+）” 评级。三位投资分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “持有”，共识目标股价为 3.83 美元。</p>
</div><p>Get <strong>Sangamo Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sangamo Therapeutics</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Research Report on SGMO</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SGMO 的最新研究报告</strong></p>
</div><h2>Sangamo Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Sangamo Therapeutics 股票表现</h2>
</div><p>NASDAQ SGMO opened at $0.44 on Friday. The business's 50 day moving average price is $0.59 and its 200-day moving average price is $0.56. Sangamo Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $2.84. The company has a market cap of $149.64 million, a P/E ratio of -1.53 and a beta of 1.25.</p>
<div class="lb-trans"><p>纳斯达克 SGMO 在周五开盘价为 0.44 美元。该公司的 50 日移动平均价格为 0.59 美元，200 日移动平均价格为 0.56 美元。Sangamo Therapeutics 的 52 周最低价为 0.41 美元，52 周最高价为 2.84 美元。该公司的市值为 1.4964 亿美元，市盈率为-1.53，贝塔值为 1.25。</p>
</div><p>Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.08). Sangamo Therapeutics had a negative return on equity of 293.05% and a negative net margin of 77.48%.The firm had revenue of $0.58 million for the quarter, compared to analysts' expectations of $34.40 million. As a group, equities analysts predict that Sangamo Therapeutics will post -0.46 EPS for the current year.</p>
<div class="lb-trans"><p>Sangamo Therapeutics（纳斯达克代码：SGMO - 获取免费报告）在 11 月 6 日发布了其季度财报。这家生物制药公司报告季度每股收益为（0.11 美元），低于共识预期的（0.03 美元）0.08 美元。Sangamo Therapeutics 的股本回报率为-293.05%，净利润率为-77.48%。该公司季度收入为 58 万美元，而分析师预期为 3440 万美元。整体来看，股票分析师预测 Sangamo Therapeutics 在本年度将发布-0.46 美元的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Sangamo Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Sangamo Therapeutics 的看法</h2>
</div><p>Several large investors have recently modified their holdings of SGMO. Golden State Equity Partners lifted its position in shares of Sangamo Therapeutics by 5.4% in the 2nd quarter. Golden State Equity Partners now owns 391,943 shares of the biopharmaceutical company's stock worth $212,000 after purchasing an additional 20,000 shares during the period. World Investment Advisors raised its stake in Sangamo Therapeutics by 88.5% in the third quarter. World Investment Advisors now owns 42,611 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 20,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Sangamo Therapeutics by 30.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 90,550 shares of the biopharmaceutical company's stock worth $48,000 after buying an additional 21,300 shares during the period. Wealth Management Associates Inc. boosted its position in Sangamo Therapeutics by 9.1% during the 3rd quarter. Wealth Management Associates Inc. now owns 335,800 shares of the biopharmaceutical company's stock valued at $226,000 after acquiring an additional 28,000 shares in the last quarter. Finally, Meritage Portfolio Management increased its holdings in shares of Sangamo Therapeutics by 37.3% in the 2nd quarter. Meritage Portfolio Management now owns 127,000 shares of the biopharmaceutical company's stock valued at $69,000 after acquiring an additional 34,500 shares during the period. Institutional investors own 56.92% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近调整了对 SGMO 的持股。Golden State Equity Partners 在第二季度将其在 Sangamo Therapeutics 的持股增加了 5.4%。Golden State Equity Partners 目前拥有 391,943 股该生物制药公司的股票，价值 212,000 美元，在此期间又购买了 20,000 股。World Investment Advisors 在第三季度将其在 Sangamo Therapeutics 的持股增加了 88.5%。World Investment Advisors 目前拥有 42,611 股该生物制药公司的股票，价值 29,000 美元，在上个季度又购买了 20,000 股。Wealth Enhancement Advisory Services LLC 在第二季度将其在 Sangamo Therapeutics 的持股增加了 30.8%。Wealth Enhancement Advisory Services LLC 目前拥有 90,550 股该生物制药公司的股票，价值 48,000 美元，在此期间又购买了 21,300 股。Wealth Management Associates Inc.在第三季度将其在 Sangamo Therapeutics 的持股增加了 9.1%。Wealth Management Associates Inc.目前拥有 335,800 股该生物制药公司的股票，价值 226,000 美元，在上个季度又收购了 28,000 股。最后，Meritage Portfolio Management 在第二季度将其在 Sangamo Therapeutics 的持股增加了 37.3%。Meritage Portfolio Management 目前拥有 127,000 股该生物制药公司的股票，价值 69,000 美元，在此期间又收购了 34,500 股。机构投资者持有该公司 56.92% 的股票。</p>
</div><h2>Sangamo Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Sangamo Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.</p>
<div class="lb-trans"><p>Sangamo Therapeutics, Inc.是一家临床阶段的基因治疗公司，专注于将科学转化为药物，以改变美国患者及其家庭的生活，这些患者受到严重疾病的困扰。该公司的临床阶段产品候选者包括 ST-920，一种基因治疗产品候选者，目前正在进行针对 Fabry 病的 1/2 期临床研究；TX200，一种嵌合抗原受体工程调节性 T 细胞（CAR-Treg）治疗产品候选者，目前正在进行针对 HLA-A2 不匹配肾移植中免疫介导排斥的 1/2 期临床研究；SB-525，一种基因治疗产品候选者，目前正在进行针对中度至重度血友病 A 的 3 期临床试验；BIVV003，一种锌指核酸酶基因编辑细胞治疗产品候选者，目前正在进行针对镰状细胞病的 1/2 期 PRECIZN-1 临床研究。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Sangamo Therapeutics</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Sangamo Therapeutics</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>如果你等到下跌，Micron Technology 可能会让你错过机会</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dNTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SGMO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sangamo Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sangamo Therapeutics 吗？</h2>
</div><p>Before you consider Sangamo Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Sangamo Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sangamo Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Sangamo Therapeutics 并不在名单上。</p>
</div><p>While Sangamo Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sangamo Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Sangamo Therapeutics（纳斯达克代码：SGMO）被 Wall Street Zen 下调至强烈卖出评级